Sunday, November 11, 2012

2575 - AMICOR 15


Últimas postagens AMICOR 15

Proton Decay?

Aloyzio AchuttiemAMICOR - 11 minutos atrás
How the death of one tiny particle could end the universe *Esther Inglis-Arkell* No one has observed any evidence for proton decay. That might be disappointing professionally for physicists, but it's good news for the universe. If it turns out to be possible, proton decay could be the beginning of the end of everything. Here's why. How do we start with protons and end with the end of the universe? We begin with what's in those protons. Inside protons are quarks. Quarks are one of the two most basic particles we can find. Quarks are subject to the strong force, the force that keeps a... mais »

Donepezil

Aloyzio AchuttiemAMICOR - 24 minutos atrás
FDA Rejects Petition to Pull High-Dose Donepezil Megan Brooks Nov 09, 2012Authors & Disclosures The US Food and Drug Administration (FDA) has rejected a petition by the consumer advocacy group Public Citizen requesting that the agency pull the 23-mg dose of the Alzheimer's disease drug donepezil (*Aricept*, Eisai/Pfizer) from the market because of safety concerns. The FDA action comes roughly 2 months after Public Citizen sued the FDA for not responding to its petition, as reported previously by *Medscape Medical News*. In a response letter dated November 6, 2012, to Sidney Wolfe,... mais »

to correct errors in a person’s genetic code

Aloyzio AchuttiemAMICOR - 36 minutos atrás
First therapy in the western world to correct errors in a person’s genetic code approved November 5, 2012 [image: Creation of the adeno-associated virus (AAV) vector (credit: uniQure),] European regulators have approved the first therapy in the western world that can correct errors in a person’s genetic code, according to Amsterdam-based uniQure (formerly Amsterdam Molecular Therapeutics), Europe has approved Glybera for treatment of Lipoprotein Lipase Deficiency (LPLD), a very rare, inherited disease. Patients with LPLD are unable to metabolize the fat particles carried in their … m... mais »

Immunity to Cancer

Aloyzio AchuttiemAMICOR - 44 minutos atrás
Blind mole rats may hold key to cancerNovember 6, 2012 [image: Palestine_Mole-rat_1] Blind mole rat (credit: Bassem18/Wikimedia Commons) Some 23% of humans die of cancer, but blind mole rats — which can live for 21 years, an impressive age among rodents — seem to be immune to the disease. Cell cultures from two species of blind mole rat,* Spalax judaei* and* Spalax golani*, behave in ways that render them impervious to the growth of tumors, according to work by Vera Gorbunova at the University of Rochester, *Nature News* reports. “These animals are subject to terrific stresses undergr... mais »

Drugs and Memory

Aloyzio AchuttiemAMICOR - 50 minutos atrás
Are you elderly and having memory or concentration problems?November 7, 2012 [image: 800px-Medicine_Drugs.svg] (Credit: Wikimedia Commons) They might be caused by common medications used to treat insomnia, anxiety, itching or allergies, according to Dr. Cara Tannenbaum, Research Chair at the Institut universitaire de gériatrie de Montréal (IUGM, Montreal Geriatric University Institute) and Associate Professor of Medicine and Pharmacy at the University of Montreal(UdeM). Up to 90 percent of people over the age of 65 take at least one prescription medication. Eighteen percent of people ... mais »

Alzheimer

Aloyzio AchuttiemAMICOR - 1 hora atrás
New stem-cell-derived cells hold promise for Alzheimer’s, other brain diseasesNovember 9, 2012 Choroid plexus epithelial cells generated in a culture medium using embryonic stem cells (credit: Edwin S. Monuki and Momoko Watanabe/USPTO) UC Irvine researchers have created a new stem cell-derived cell type with unique promise for treating neurodegenerative diseases such as Alzheimer’s. Dr. Edwin Monuki of UCI’s Sue & Bill Gross Stem Cell Research Center and colleagues developed these cells — called choroid plexus epithelial cells (CPECs) — from existing mouse and human embryonic stem ce... mais »

Universe

Aloyzio AchuttiemAMICOR - 2 dias atrás
Star Formation Slumps to 1/30th of Its Peak *Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.* enlarge *This diagram indicates the changing ‘GDP’ of the Universe over time. The new results indicate that, measured by mass, the production rate of stars has dropped by 97% since its peak 11 billion years ago. (Credit: D. Sobral)*ScienceDaily (Nov. 6, 2012) *Universe over time. The new results indicate that, measured by mass, the production rate of stars has dropped by 97% since its peak 11 billion years ago. (Credit: D. Sobral)* ... mais »

Epidemia Influenza RS 2012

Aloyzio AchuttiemAMICOR - 3 dias atrás
*Epidemia de Influenza de 2012 no Rio Grande do Sul* * * *Qualquer comentário será bem vindo e poderá ser enviado para miazambuja@terra.com.br* O objetivo de publicar este estudo sobre *a Epidemia de Influenza de 2012 no Rio Grande do Sul *na internet, e na forma de slides, é favorecer a comunicação rápida dos achados deste inquérito epidemiológico e da hipótese levantada a partir dele. Uma versão escrita será eventualmente submetida à publicação. att *Maria Inês Azambuja, Dep. Medicina Social, UFRGS* Novembro de 2012.

AMG 145 (Amgen) Cholesterol LDL

Aloyzio AchuttiemAMICOR - 4 dias atrás
New Drug Class Cuts LDL Cholesterol By Chris Kaiser, Cardiology Editor, MedPage Today Published: November 06, 2012 Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston ............. "We saw three positive trials, but they are phase II trials showing efficacy and a fair amount of information on safety," he said. "Now we need longer-term safety data and cardiovascular outcomes." In all the trials, patients experienced a robust drop in LDL within the first 2 weeks, which then was sustained out to 12 weeks. AMG 145 (Amgen) and RN136 (... mais »

Serelaxin in HF

Aloyzio AchuttiemAMICOR - 4 dias atrás
AHA: Is Novel HF Drug Too Good to Be True? By Chris Kaiser, Cardiology Editor, MedPage Today Published: November 06, 2012 Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco Click the bottom right corner of the video player for full screen. LOS ANGELES -- A novel drug for acute heart failure could be a "game-changer," but there are concerns about whether the mortality benefit is real or chance, experts said here. The RELAX-AHF (RELAXin in Acute Heart Failure) trial -- which is testing serelaxin, a drug that relaxes blood ve... mais »

Porto Alegre

Aloyzio AchuttiemAMICOR - 5 dias atrás
*Link para fotos aéreas 360º de Porto Alegre:* http://www.auroraimagens.com.br/tour/portoalegre/ *Referência enviada por nosso filho Luiz Eduardo Robinson Achutti*

Bacterial medicine

Aloyzio AchuttiemAMICOR - 6 dias atrás
Treating disease with microbesBugs in the system. Bacterial medicine is starting to emergeNov 3rd 2012 | from the print editionOlONE of the crucial transitions of modern health care was from herbal to chemical medicine. Doctors had known for millennia that willow bark and poppy sap relieve pain. But it was not until the late 19th century, when Felix Hoffman synthesised versions of their active ingredients, namely acetylsalicylic acid and diamorphine (or aspirin and heroin, as they are more commonly known), that proper pharmaceutical science got going. Just possibly, something simil... mais »

RF Primary Prevention

Aloyzio AchuttiemAMICOR - 6 dias atrás
Treat kids with sore throats to curb RF in South AfricaNOVEMBER 4, 2012 Lisa Nainggolan *Los **Angeles, CA *- A strategy of treating all children in developing countries who present with a sore throat with a one-off injection of penicillin to prevent development of acute rheumatic fever and rheumatic heart disease in a minority would be cost-effective and save lives, a new statistical analysis shows. [image: Dr Thomas Gaziano] Dr Thomas Gaziano And factoring in the existence of one or more symptoms suggestive of "strep throat"—such as enlarged lymph nodes, absence of rhinitis, and ab... mais »

Spacetime

Aloyzio AchuttiemAMICOR - 6 dias atrás
Looking Beyond Space and Time to Cope With Quantum Theory ScienceDaily (Oct. 28, 2012) — Physicists have proposed an experiment that could force us to make a choice between extremes to describe the behaviour of the Universe. The proposal comes from an international team of researchers from Switzerland, Belgium, Spain and Singapore, and is published October 28 in *Nature Physics*. It is based on what the researchers call a 'hidden influence inequality'. This exposes how quantum predictions challenge our best understanding about the nature of space and time, Einstein's theory of rel... mais »

No comments:

Post a Comment